Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fischer, L.
Right arrow Articles by Korfel, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fischer, L.
Right arrow Articles by Korfel, A.
Related Collections
Right arrow All Oncology
Right arrow Primary brain tumor
Right arrow Chemotherapy-tumor
NEUROLOGY 2004;62:1885-1887
© 2004 American Academy of Neurology
Brief Communications

Response of relapsed or refractory primary central nervous system lymphoma (PCNSL) to topotecan

L. Fischer, MD, E. Thiel, MD, H. A. Klasen, MD, H. Kirchen, MD, K. Jahnke, MD and A. Korfel, MD

From the Department of Hematology, Oncology, and Transfusion Medicine (Drs. Fischer, Thiel, Jahnke, and Korfel), Klinikum Benjamin Franklin, Freie Universität Berlin, Germany; Department of Radiotherapy and Oncology (Dr. Klasen), Pius-Hospital, Oldenburg, Germany; and Department of Gastroenterology, Hematology, and Oncology (Dr. Kirchen), Krankenhaus der Barmherzigen Brüder, Trier, Germany.

Address correspondence and reprint requests to Dr. Lars Fischer, Innere Medizin III, Hämatologie, Onkologie, Transfusionsmedizin, Klinikum Benjamin Franklin, Hindenburgdamm 30, 12200 Berlin, Germany; e-mail: lfischer{at}zedat.fu-berlin.de

The authors treated 16 immunocompetent patients with refractory or relapsed primary CNS lymphoma with topotecan. Fifteen patients had been pretreated with up to three chemotherapy regimens, three of them additionally with whole brain irradiation (WBI), and one with WBI alone. Four complete remissions and two partial remissions were achieved. Progression-free survival was 20% at 6 months and 13% at 12 months.

Received March 3, 2003. Accepted in final form January 8, 2004.




This article has been cited by other articles:


Home page
 The OncologistHome page
M. Sierra del Rio, A. Rousseau, C. Soussain, D. Ricard, and K. Hoang-Xuan
Primary CNS Lymphoma in Immunocompetent Patients
Oncologist, May 1, 2009; 14(5): 526 - 539.
[Abstract] [Full Text] [PDF]

Home page
 Therapeutic Advances in Neurological DisordersHome page
U. Schlegel
Review: Primary CNS lymphoma
Therapeutic Advances in Neurological Disorders, March 1, 2009; 2(2): 93 - 104.
[Abstract] [PDF]

Home page
 JCOHome page
C. Soussain, K. Hoang-Xuan, L. Taillandier, E. Fourme, S. Choquet, F. Witz, O. Casasnovas, B. Dupriez, B. Souleau, A.-L. Taksin, et al.
Intensive Chemotherapy Followed by Hematopoietic Stem-Cell Rescue for Refractory and Recurrent Primary CNS and Intraocular Lymphoma: Societe Francaise de Greffe de Moelle Osseuse-Therapie Cellulaire
J. Clin. Oncol., May 20, 2008; 26(15): 2512 - 2518.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
L. Fischer, E. Thiel, H.-A. Klasen, J. Birkmann, K. Jahnke, P. Martus, and A. Korfel
Prospective trial on topotecan salvage therapy in primary CNS lymphoma
Ann. Onc., July 1, 2006; 17(7): 1141 - 1145.
[Abstract] [Full Text] [PDF]

Home page
 ASH Education BookHome page
L. M. DeAngelis and F. M. Iwamoto
An Update on Therapy of Primary Central Nervous System Lymphoma
Hematology, January 1, 2006; 2006(1): 311 - 316.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2004 by AAN Enterprises, Inc.